Tempus's $1.
5B Bet on Personalis: A Melanoma Win Raises More Questions Than Answers The recent Phase 3 trial results from Moderna and Merck have sent shockwaves through the biotech sector, but for Tempus AI, one of the companies most directly impacted by this development is actually a separate player in the personalized cancer therapy space.
Personalis, which has been a key partner in the clinical development program for its therapy intismeran autogene (V940), combined with Keytruda, saw its stock jump after the news.